The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
Open accessAbstract
We compared the efficacy of intensified chemotherapy followed by myeloablative therapy and autologous stem cell rescue with intensified chemotherapy alone in patients newly diagnosed with multiple myeloma. There were 261 eligible patients younger than 66 years with stage II/III multiple myeloma who were randomized after remission induction therapy with vincristine, adriamycin, dexamethasone (VAD) to receive intensified chemotherapy, that is, melphalan 140 mg/m2 administered intravenously in 2 doses of 70 mg/m2 (intermediate-dose melphalan [IDM]) without stem cell rescue (n = 129) or the same regimen followed by myeloablative therapy consisting of cyclophosphamide, total body irradiation, and autologous stem cell reinfusion (n = 132). Interferon-α–2a was given as maintenance. Of the eligible patients, 79% received both cycles of IDM and 79% of allocated patients actually received myeloablative treatment. The response rate (complete remission [CR] plus partial remission [PR]) was 88% in the intensified chemotherapy group versus 95% in the myeloablative treatment group. CR was significantly higher after myeloablative therapy (13% versus 29%; P = .002). With a median follow-up of 33 months (range, 8-65 months), the event-free survival (EFS) was not different between the treatments (median 21 months versus 22 months; P = .28). Time to progression (TTP) was significantly longer after myeloablative treatment (25 months versus 31 months; P = .04). The overall survival (OS) was not different (50 months versus 47 months; P = .41). Intensified chemotherapy followed by myeloablative therapy as first-line treatment for multiple myeloma resulted in a higher CR and a longer TTP when compared with intensified chemotherapy alone. However, it did not result in a better EFS and OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Cited by
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Giralt, S., Costa, L., Schriber, J., DiPersio, J., Maziarz, R., McCarty, J., Shaughnessy, P., Snyder, E., Bensinger, W., Copelan, E., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2013.10.013 · Cited by 407
Jagannath, S., Durie, B. G. M., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05540.x · Cited by 398
Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2509 · Cited by 370
Metadata
- Authors
- Segeren, C. M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A. J., Verhoef, G. E. G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H. J., Wijermans, P. W., Fibbe, W. E., Wittebol, S., Schouten, H. C., Kooy, M. V. M., Biesma, D. H., Baars, J. W., Slater, R., Steijaert, M. M. C., Buijt, I., & Lokhorst, H. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-03-15
- Volume
- 101
- Issue
- 6
- Pages
- 2144-2151
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2155618453
- Cited by
- 163
- References
- 2
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. https://app.cochat.ai/papers/10.1182/blood-2002-03-0889
- The paper
- Segeren, C. M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A. J., Verhoef, G. E. G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H. J., Wijermans, P. W., Fibbe, W. E., Wittebol, S., Schouten, H. C., Kooy, M. V. M., Biesma, D. H., Baars, J. W., Slater, R., Steijaert, M. M. C., Buijt, I., & Lokhorst, H. M. (2003). Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood. https://doi.org/10.1182/blood-2002-03-0889
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.